642 related articles for article (PubMed ID: 32605647)
21. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
Fries C; Burack WR
Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.
Logan AC; Zhang B; Narasimhan B; Carlton V; Zheng J; Moorhead M; Krampf MR; Jones CD; Waqar AN; Faham M; Zehnder JL; Miklos DB
Leukemia; 2013 Aug; 27(8):1659-65. PubMed ID: 23419792
[TBL] [Abstract][Full Text] [Related]
23. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
24. Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring.
Derrieux C; Gish A; Caulier A; Grardel N; Garidi R; Joris M; Assouan D; Poulain S; Decool G; Ferret Y; Caillault-Venet A; Marolleau JP; Preudhomme C; Boyer T
Br J Haematol; 2020 Nov; 191(3):506-509. PubMed ID: 32754904
[No Abstract] [Full Text] [Related]
25. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
[TBL] [Abstract][Full Text] [Related]
26. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.
Liu Y; Ho C; Yu W; Huang Y; Miller J; Gao Q; Syed M; Ma Y; Wang M; Maciag L; Petrova-Drus K; Zhu M; Yao J; Vanderbilt C; Durham B; Benhamida J; Ewalt MD; Dogan A; Roshal M; Nafa K; Arcila ME
J Mol Diagn; 2024 Mar; 26(3):168-178. PubMed ID: 38103591
[TBL] [Abstract][Full Text] [Related]
27. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
[TBL] [Abstract][Full Text] [Related]
28. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
Wu D; Emerson RO; Sherwood A; Loh ML; Angiolillo A; Howie B; Vogt J; Rieder M; Kirsch I; Carlson C; Williamson D; Wood BL; Robins H
Clin Cancer Res; 2014 Sep; 20(17):4540-8. PubMed ID: 24970842
[TBL] [Abstract][Full Text] [Related]
29. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
30. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
[TBL] [Abstract][Full Text] [Related]
31. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
Wolf J; Fonseca R; Muffly L
Clin Adv Hematol Oncol; 2020 Mar; 18 Suppl 9(3):1-16. PubMed ID: 33843875
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.
Hussaini MO; Srivastava J; Lee LW; Nishihori T; Shah BD; Alsina M; Pinilla-Ibarz J; Shain KH
Arch Pathol Lab Med; 2022 Apr; 146(4):485-493. PubMed ID: 34343238
[TBL] [Abstract][Full Text] [Related]
33. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
[TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia.
Donovan JW; Ladetto M; Zou G; Neuberg D; Poor C; Bowers D; Gribben JG
Blood; 2000 Apr; 95(8):2651-8. PubMed ID: 10753847
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
[TBL] [Abstract][Full Text] [Related]
36. How I investigate minimal residual disease in acute lymphoblastic leukemia.
Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.
Alley CL; Wang E; Dunphy CH; Gong JZ; Lu CM; Boswell EL; Burchette J; Lagoo AS
Arch Pathol Lab Med; 2013 Apr; 137(4):503-17. PubMed ID: 23544940
[TBL] [Abstract][Full Text] [Related]
40. Profile of immunoglobulin heavy chain variable gene repertoires and highly selective detection of malignant clonotypes in acute lymphoblastic leukemia.
Greenberg SJ; Choi Y; Ballow M; Du TL; Ward PM; Rickert MH; Frankel S; Bernstein SH; Brecher ML
J Leukoc Biol; 1995 Jun; 57(6):856-64. PubMed ID: 7790768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]